|
BRIEF-GSK submits application for Japanese approval of asthma drug
Reuters May 22 GlaxoSmithKline Plc : * Submits Japan regulatory application for mepolizumab in severe eosinophilic asthma. * Mepolizumab is an anti il-5 monoclonal antibody delivered in a 100mg fixed dose via a subcutaneous injection every four weeks. |
View full post on asthma – Google News